small slit made skin hemostatic mechanisms necessary coagulation activated
without aid external pressure bleeding usually stops within minutes
test performed using disposable template produces uniform incision
incision either horizontal vertical placed lateral aspect forearm cm antecubital fossa blood pressure cuff inflated approximately mm hg
blood may absorbed skin care must taken avoid pressure
time measured moment incision moment bleeding stops
time may vary based commercial template used direction incision location arm
institution must establish upper limits normal
vascular platelet phase hemostasis consists primary vasoconstriction serves decrease blood flow followed adherence platelets ruptured endothelium adhesion aggregation
platelet aggregate called platelet plug stops bleeding forms matrix clot
bleeding time excellent screening test vascular platelet phase hemostasis
depends intact vasospastic response small vessel adequate number functionally active platelets
patients abnormalities vascular platelet phase hemostasis present purpura petechiae ecchymoses spontaneous bruising
may mucosal bleeding fundus hemorrhages
commonly problem either thrombocytopenia easily evaluated platelet count abnormal platelet function diagnosed platelet function studies
common acquired platelet function abnormalities drug induced aspirin nonsteroidal anti inflammatory agents uremia
common hereditary abnormality von willebrand disease
vitro teststhe activated partial thromboplastin time aptt prothrombin time pt thrombin time ttmeasure time elapsed activation coagulation cascade figure
different points generation fibrin
aptt measures time necessary generate fibrin initiation intrinsic pathway figure
activation factor xii accomplished external agent e g kaolin capable activating factor xii without activating factor vii
since platelet factors necessary cascade function normally test performed presence phospholipid emulsion takes place factors
classic partial thromboplastin time depends contact glass tube activation
since considered difficult variable control activated test uses external source activation
citrated plasma activating agent phospholipid added together incubated °c
calcium added time necessary clumping kaolin measured
normal time usually reported less seconds depending technique used
fact normal range seconds e g decreased values short may also abnormal
test abnormal presence reduced quantities factors xii ix xi viii x v prothrombin fibrinogen integral parts intrinsic common pathway
usually prolonged patient less approximately normal activity
also abnormal presence circulating inhibitor intrinsic pathway factors
differentiation inhibitors factor depletion important best accomplished mixing study patient normal plasma combined ratio test repeated mixed sample
abnormal value corrected completely problem factor deficiency
result change abnormality corrected partially inhibitor present
difference stems mentioned fact aptt normal presence normal activity
aptt good screening test inherited acquired factor deficiencies
inherited disorders including classic hemophilia factor viii deficiency hemophilia b factor ix deficiency christmas disease well known diseases aptt prolonged
intrinsic common pathway factors may also congenitally absent
conditions rare described factors
number kindreds abnormalities factor xii activation described
usually associated prolonged aptt without clinical signs bleeding
acquired factor deficiency common
vitamin k deficiency liver dysfunction iatrogenic anticoagulation warfarin common
factor depletion may also occur setting disseminated intravascular coagulation dic prolonged bleeding massive transfusion
prolonged aptt completely normalized addition normal plasma explained presence circulating inhibitor coagulation
presence inhibitors almost always acquired exact nature always apparent
clinical point view common inhibitors considered antithrombins
compounds inhibit activity thrombin conversion fibrinogen fibrin figure
two common inhibitors heparin acts naturally occurring protein antithrombin iii iii fibrin degradation products fdp formed action plasmin fibrin clot usually present elevated concentrations dic primary fibrinolysis
inhibitors appear antibodies
easiest understand antibody factor viii patients hemophilia treated factor viii concentrate
inhibitors factors described variety diseases follow variable course
characterized immunoglobulins
particular problem may seen patients suffering systemic lupus erythematosus
patients may present prolonged aptt without evidence bleeding
present thrombosis
abnormality corrected normal plasma referred lupus anticoagulant
phenomenon represent vivo problem coagulation cascade
rather laboratory abnormality caused presence serum constituent interferes vitro partial thromboplastin test
occasionally reported value aptt lower normal
shortened time may reflect presence increased levels activated factors context hypercoagulable state
seen patients early stages dic considered diagnostic entity
pt measures time necessary generate fibrin activation factor vii
measures integrity extrinsic common pathways factors vii v x prothrombin fibrinogen
citrated plasma activating agent usually thromboplastin extracted animal brain incubated °c
plasma recalcified time measured fibrin filaments observed
laboratory normal value usually seconds
interpretation prolonged aptt prolonged pt may reflect either factor deficiency circulating inhibitor coagulation
distinction made repeating test mix normal plasma
test sensitive aptt deficient levels factors relatively small drop factor vii levels may prolong pt
inherited deficiency factor vii rare bleeding disorder characterized prolonged pt normal aptt
pt completely corrects mixed normal plasma
acquired deficiencies usually related liver disease warfarin therapy depletion secondary consumptive coagulopathy severe bleeding massive transfusion
circulating inhibitors often directed factor x thrombin
common heparin products fibrinolysis
presence prolonged pt completely corrected normal mixing study
test measures time necessary drive reaction fibrinogen fibrin presence thrombin
measures integrity reaction isolates abnormality either decrease normal fibrinogen inhibitor activation
citrated plasma incubated °c thrombin added solution
time measured addition thrombin generation fibrin filaments
calcium unnecessary
abnormalities explained one three ways deficient fibrinogen mgdl abnormal fibrinogen inhibitor reaction
tests coagulation cascade mixing study normalizes prolonged time one dealing factor deficiency
pertains fibrinogen however one must distinguish decrease normal fibrinogen production abnormal fibrinogen dysfibrinogenemia
acquired deficiency fibrinogen usually due consumptive coagulopathy less often severe liver disease
hereditary deficiencies exist variable clinical presentations
afibrinogenemia often fatal childhood condition
abnormal fibrinogen dysfibrinogenemia acquired inherited
acquired form usually found association severe liver disease reported diseases
congenital form rare usually autosomal dominant
discordance immunologic physiologic measurements fibrinogen key diagnosis
common acquired inhibitors reaction heparin fibrin degradation products fdp
effect heparin eliminated catalyzing reaction reptilase unlike thrombin insensitive heparin
fdp commonly seen consumptive coagulopathies primary fibrinolytic states
described figure coagulation cascade efficient system generating fibrin
equally important system limits process neutralizes activated factors stops propagation clot keeps process coagulation confined area endothelial rupture
fibrinolysis accomplished action plasmin fibrin polymer
plasmin generated plasminogen produced liver action plasminogen activators
compounds present endothelial cells reaction accelerated presence fibrin
thus generation fibrin appears turn fibrinolytic process localize formation fibrin gel
marker fibrinolysis fibrin degradation products fdp also known fibrin split products fsp quantified test based latex agglutination
test uses antibodies fsp measured using serial dilutions
serum prepared series dilutions e g
latex particles onto absorbed antibodies fsp added
agglutination seen test positive dilution
test reported dilute sample agglutinates
normal value less
although well standardized easy perform fsp value may difficult interpret
action thrombin fibrinogen cleave protein produce smaller compounds called fibrinopeptides plus fibrin monomer
monomer polymerizes form fibrin gel
gel stabilized action factor xiii activated thrombin
action plasmin cleave fibrinogen fibrin
action localized activation site endothelial rupture tight association plasminogen fibrin
activity fibrinogen forms small fragments e
action fibrin polymer form larger fragments
fragments anticoagulants formed site coagulation serve inhibit action thrombin fibrinogen form fibrin
also measured technique described
increased fdp laboratory expression increased fibrinolysis
may part local problem fibrin generation brain trauma chronic bleeding vascular thrombosis prostate surgery uterine disorders malignancy systemic process usually dic
patients severe liver disease increased fibrinolysis basis poor clearance circulating plasminogen activators
least two systems important controlling hemostatic process
antithrombin iii iii protein produced liver
binds thrombin activated factor x irreversibly
interaction accelerated heparin may associated ruptured endothelial cells
iii quantified congenitally absent patients prone thrombosis
technical aspects measurement beyond scope chapter
similar protein protein c appears inactivate factors v viii reaction catalyzed thrombin localized area endothelial rupture
vitamin k dependent protein produced liver
measurement still considered research tool
proteins locally activated site endothelial rupture
serve prevent escape circulation activated factors limit propagation clot